CDER Guidance Agenda 2004: Pregnancy, Pediatric Studies Are Priorities
Executive Summary
FDA is planning several new guidances to refine recommendations for drug studies in children and pregnant women during 2004, the Center for Drug Evaluation & Research's guidance agenda for the coming year indicates
You may also be interested in...
Pregnancy Adverse Events Could Be Shown Separately Under Labeling Reform
Pregnancy-related labeling reforms could include displaying birth defect incidence information in a separate section from general adverse events, Center for Drug Evaluation & Research Office of New Drugs Pregnancy Labeling Team Leader Kathleen Uhl, MD, suggested
Pregnancy Adverse Events Could Be Shown Separately Under Labeling Reform
Pregnancy-related labeling reforms could include displaying birth defect incidence information in a separate section from general adverse events, Center for Drug Evaluation & Research Office of New Drugs Pregnancy Labeling Team Leader Kathleen Uhl, MD, suggested
FDA Assessing QT Study Designs With Clinical Trial Simulations
FDA hopes to use clinical trial simulations to develop study designs to more accurately predict drugs' QT prolongation risk